These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 15660477)

  • 1. Impediments to the diffusion of innovative medicines in Europe.
    Schöffski O
    Pharmacoeconomics; 2004; 22(2 Suppl 2):51-64. PubMed ID: 15660477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments.
    Kandolf Sekulovic L; Peris K; Hauschild A; Stratigos A; Grob JJ; Nathan P; Dummer R; Forsea AM; Hoeller C; Gogas H; Demidov L; Lebbe C; Blank C; Olah J; Bastholt L; Herceg D; Neyns B; Vieira R; Hansson J; Rutkowski P; Krajsova I; Bylaite-Bucinskiene M; Zalaudek I; Maric-Brozic J; Babovic N; Banjin M; Putnik K; Weinlich G; Todorovic V; Kirov K; Ocvirk J; Zhukavets A; Kukushkina M; De La Cruz Merino L; Ymeri A; Risteski M; Garbe C
    Eur J Cancer; 2017 Apr; 75():313-322. PubMed ID: 28264791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innovation in health care: time for a gut check.
    Salehizadeh B
    Clin Gastroenterol Hepatol; 2012 Jan; 10(1):27-9. PubMed ID: 22177468
    [No Abstract]   [Full Text] [Related]  

  • 4. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
    Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
    Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Availability of medicines in public sector health facilities of two North Indian States.
    Prinja S; Bahuguna P; Tripathy JP; Kumar R
    BMC Pharmacol Toxicol; 2015 Dec; 16():43. PubMed ID: 26699711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacoeconomic analyses--chance or 4th hurdle for innovative drugs].
    Krammer H
    Wien Med Wochenschr; 2006 Dec; 156(23-24):606-11. PubMed ID: 17211764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Introducing Key Elements Regarding Access to Personal Data for Scientific Research in the Perspective of Developing Innovative Medicines.
    Herveg J; Altavilla A
    Eur J Health Law; 2020 May; 27(3):195-212. PubMed ID: 33652399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Risk-sharing schemes: a new paradigm in adopting innovative pharmaceuticals].
    Hammerman A; Greenberg D
    Harefuah; 2012 Jun; 151(6):364-7, 376. PubMed ID: 22991869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Access to essential medicines to treat chronic respiratory disease in low-income countries.
    Bissell K; Perrin C; Beran D
    Int J Tuberc Lung Dis; 2016 Jun; 20(6):717-28. PubMed ID: 27155173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Essential medicines for childhood cancer in Europe: a pan-European, systematic analysis by SIOPE.
    Otth M; Brack E; Kearns PR; Kozhaeva O; Ocokoljic M; Schoot RA; Vassal G;
    Lancet Oncol; 2022 Dec; 23(12):1537-1546. PubMed ID: 36332647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Will the innovative medicines initiative really deliver innovative medicines?
    Wilkinson E
    Mol Oncol; 2008 Oct; 2(3):203-5. PubMed ID: 19383340
    [No Abstract]   [Full Text] [Related]  

  • 15. [100 essential drugs. An internal medicine approach].
    Thomas M; Arlet P; Aumaitre O; Cosserat J; Grosbois B; Guillevin L; Kettaneh A; Le Jeunne C; Massot C; Morlat P
    Rev Med Interne; 2013 Aug; 34(8):460-4. PubMed ID: 23643757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New trends and challenges in the European regulation of innovative medicines.
    Enzmann H
    Regul Toxicol Pharmacol; 2016 Oct; 80():314-20. PubMed ID: 27237379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Europe provides 172m euro for research into innovative medicines.
    Watson R
    BMJ; 2011 Mar; 342():d1577. PubMed ID: 21393337
    [No Abstract]   [Full Text] [Related]  

  • 18. [Innovative treatment in psychiatry - a chance for integrated health care].
    Deister A; Wilms B
    Psychiatr Prax; 2015 Jan; 42(1):8-10. PubMed ID: 25584998
    [No Abstract]   [Full Text] [Related]  

  • 19. Mega-mergers in the pharmaceutical industry. In whose interests?
    Po AL
    Pharmacoeconomics; 1998 Oct; 14(4):349-55. PubMed ID: 10344903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.